TBPH
Theravance Biopharma Inc.
$14.07
+$0.19(+1.37%)
66
Overall
--
Value
66
Tech
--
Quality
Market Cap
$698.51M
Volume
377.75K
52W Range
$7.88 - $14.55
Target Price
$20.00
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $42.1M | $48.6M | $15.4M | $60.4M | $73.4M | $71.9M | $55.3M | $51.3M | $57.4M | $64.4M | ||
| Total Revenue | $9.4M | $17.6M | $15.4M | $60.4M | $73.4M | $71.9M | $55.3M | $51.3M | $57.4M | $64.4M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-4.7M | $-2.9M | $-6.0M | -- | -- | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $37.5M | $45.8M | $15.4M | $60.4M | $73.4M | $71.9M | $55.3M | $51.3M | $57.4M | $64.4M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-224.0M | $-229.1M | $-275.5M | $-299.1M | $325.3M | $369.6M | $313.1M | $143.3M | $113.5M | $111.3M | ||
| Research & Development | $129.2M | $141.7M | $173.9M | $201.3M | $219.2M | $261.0M | $193.7M | $63.4M | $40.6M | $37.6M | ||
| Research Expense | $129.2M | $141.7M | $173.9M | $201.3M | $219.2M | $261.0M | $193.7M | $63.4M | $40.6M | $37.6M | ||
| Selling, General & Administrative | $90.2M | $84.5M | $95.6M | $97.1M | $106.1M | $108.7M | $99.3M | $67.1M | $70.1M | $69.2M | ||
| Selling & Marketing Expenses | $90.2M | $84.5M | $95.6M | $97.1M | $2.4M | $6.3M | $9.3M | $8.0M | $5.1M | $4.3M | ||
| General & Administrative Expenses | -- | -- | -- | -- | $106.1M | $108.7M | $99.3M | $67.1M | $70.1M | $69.2M | ||
| Promotion & Advertising | $-4.0M | $-2.5M | $-3.2M | $-1.9M | $2.4M | $6.3M | $9.3M | $8.0M | $5.1M | $4.3M | ||
| Salaries & Wages | $54.0M | $41.2M | $49.1M | $51.3M | -- | -- | $2.8M | $1.7M | $25.4M | $21.4M | ||
| Depreciation & Amortization | $-2.5M | $-2.2M | $-2.5M | $-3.0M | $3.3M | $3.3M | $3.5M | $2.6M | $1.9M | $1.6M | ||
| Depreciation & Amortization | $-2.5M | $-2.2M | $-2.5M | $-3.0M | $3.3M | $3.3M | $3.5M | $2.6M | $1.9M | $1.6M | ||
| Amortization | -- | -- | $-1.1M | $-1.2M | $3.1M | $2.0M | $1.1M | $536.0K | -- | -- | ||
| Other Operating Expenses | $-224.0M | $-229.1M | $6.0M | $715.0K | $-8.4M | $-12.7M | $-12.0M | $143.3M | $-4.1M | $-4.1M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-235.9M | $-221.6M | $-309.3M | $-290.1M | $-251.9M | $-297.8M | $-257.8M | $-92.0M | $-56.0M | $-46.9M | ||
| EBITDA | $-178.3M | $-176.0M | $-259.1M | $-212.4M | $-203.6M | $-287.8M | $-248.1M | $-79.4M | $-45.0M | $-41.0M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | $1.4M | $8.5M | $10.5M | $31.9M | $8.5M | $8.5M | $6.4M | $2.4M | -- | ||
| Net Non-Operating Interest Income/Expense | -- | $-1.4M | $-8.5M | $-10.5M | $-31.9M | $-44.6M | $-8.5M | $-2.2M | $-6.8M | -- | ||
| Gain on Sale of Securities | -- | -- | $-8.0M | $8.0M | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-631.0K | $-1.3M | $-5.0M | $-23.1M | $-42.1M | $7.2M | $61.0M | $-8.9M | $-9.1M | $-368.0K | ||
| Other Special Charges | $631.0K | $1.3M | $4.8M | $12.0M | $8.4M | $-12.6M | $1.1M | $5.5M | $9.1M | $4.9M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | $3.5M | -- | $20.1M | $12.8M | $2.7M | -- | ||
| Special Income Charges | -- | -- | $-8.0M | -- | $-3.5M | -- | $-20.1M | $-12.8M | $-2.7M | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $4.5M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-181.3M | $-179.2M | $-263.2M | $-215.6M | $-209.8M | $-294.8M | $-256.7M | $-86.4M | $-49.3M | $-44.6M | ||
| Pre-Tax Income | $-181.3M | $-180.6M | $-271.7M | $-226.1M | $-241.7M | $-286.5M | $-265.2M | $-92.8M | $-49.3M | $-44.6M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $951.0K | $10.1M | $13.7M | $-10.6M | $-5.2M | $-8.5M | $-151.0K | $9.0K | $5.9M | $11.8M | ||
| NET INCOME | ||||||||||||
| Net Income | $-236.3M | $-231.8M | $-334.6M | $-266.8M | $-236.5M | $-278.0M | $-199.4M | $872.1M | $-55.2M | $-56.4M | ||
| Net Income (Continuing Operations) | $-236.3M | $-231.8M | $-334.6M | $-266.8M | $-236.5M | $-278.0M | $-199.4M | $-92.8M | $-55.2M | $-56.4M | ||
| Net Income (Discontinued Operations) | $-236.3M | $-231.8M | $-334.6M | $-266.8M | $-236.5M | $-278.0M | $-199.4M | $872.1M | $-55.2M | $-56.4M | ||
| Net Income (Common Stockholders) | $-236.3M | $-231.8M | $-334.6M | $-266.8M | $-296.9M | $-278.0M | $-199.4M | $872.1M | $-55.2M | $-56.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-245.2M | -- | -- | $-39.7M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-228.7M | $-232.0M | $-275.5M | $-299.1M | $325.3M | $369.6M | $313.1M | $137.5M | $113.5M | $111.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $34.1M | $44.7M | $52.4M | $54.0M | $55.6M | $62.3M | $69.5M | $73.6M | $55.3M | $48.8M | ||
| Average Shares Outstanding (Diluted) | $44.2M | $54.4M | $61.4M | $54.0M | $55.6M | $62.3M | $69.5M | $73.6M | $55.3M | $48.8M | ||
| Shares Outstanding | $38.4M | $52.9M | $54.4M | $55.6M | $62.5M | $64.3M | $74.7M | $62.9M | $48.2M | $49.5M | ||
| Basic EPS | -- | -- | -- | -- | $-4.25 | $-4.46 | $-2.87 | $23.7 | $-1 | $-1.15 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-4.25 | $-4.46 | $-2.87 | $10.59 | $-2 | $-1.15 | ||
| Diluted EPS | $-5.34 | $-4.26 | $-5.45 | $-3.99 | $-4.25 | $-4.46 | $-2.87 | $23.7 | $-1 | $-1.15 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-2.87 | $10.59 | $-2 | $-1.15 | ||
| OTHER METRICS | ||||||||||||
| Acquisition Expense | -- | -- | -- | -- | $60.5M | -- | -- | -- | -- | -- | ||
| Allowances For Construction | -- | -- | -- | -- | -- | -- | $62.1M | -- | -- | -- | ||
| Basic Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | $13.11 | -- | -- | ||
| Development Expense | -- | -- | -- | -- | -- | $63.0M | -- | -- | -- | -- | ||
| Diluted Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | $13.11 | -- | -- | ||
| Earnings from equity interest | -- | -- | $170.0K | $11.2M | $33.7M | $68.4M | $104.0M | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | $170.0K | $11.2M | $33.7M | $68.4M | $104.0M | -- | -- | -- | ||
| Gain On Sale Of Business | -- | -- | -- | $6.1M | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | -- | -- | $1.2M | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | -- | -- | -- | -- | $-179.0M | -- | -- | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | -- | $65.6M | $1.9B | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | -- | -- | -- | $65.6M | $2.1B | -- | -- | ||
| Other Gand A | -- | -- | -- | -- | $106.1M | $108.7M | $99.3M | $67.1M | $70.1M | $69.2M | ||
| Other Write Off | -- | -- | -- | -- | $60.5M | $63.0M | -- | $39.7M | -- | -- | ||
| Selling Expense | $90.2M | $84.5M | $95.6M | $97.1M | -- | -- | $62.1M | -- | -- | -- | ||
| Write Down | -- | -- | $8.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | $3.5M | -- | $20.1M | $12.8M | $2.7M | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TBPH | $14.07 | +1.4% | 377.75K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Theravance Biopharma Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW